Dengqiang Lin
Overview
Explore the profile of Dengqiang Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Lin D, Xiong Y, Lin W, Zhang S, Huang S, et al.
Eur Radiol
. 2025 Feb;
PMID: 39979621
Objectives: This research focused on investigating the relationship between the Node Reporting and Data System (Node-RADS) categories, determined via preoperative CT, and the outcomes of progression-free survival (PFS) and cancer-specific...
2.
Li X, Lin J, Qi H, Dai C, Guo Y, Lin D, et al.
Insights Imaging
. 2024 Jul;
15(1):175.
PMID: 38992169
Objectives: This study aimed to assess the predictive value of radiomics derived from intratumoral and peritumoral regions and to develop a radiomics nomogram to predict preoperative nuclear grade and overall...
3.
Li X, Zhang S, Huang X, Lin D, Zhou J
Abdom Radiol (NY)
. 2024 Jun;
49(10):3485-3495.
PMID: 38842727
Purpose: This study aimed to develop and validate a computed tomography-based nomogram assessing visceral and subcutaneous adiposity for predicting outcomes in localized clear cell renal cell carcinoma (ccRCC). Methods: A...
4.
Li X, Lin J, Guo Y, Lin D, Zhou J
Curr Med Imaging
. 2024 May;
20:e15734056295913.
PMID: 38798222
Background: Evidence of the association between obesity and renal cell carcinoma progression is contradictory. The effects of renal cell carcinoma on fat distribution are still unknown. Objective: The goal of...
5.
Lin D, Lai P, Zhang W, Lin J, Wang H, Hu X, et al.
Front Oncol
. 2023 Mar;
13:1071816.
PMID: 36874101
The unpredictable biological behavior and tumor heterogeneity of metastatic renal cell carcinoma (mRCC) cause significant differences in axitinib efficacy. The aim of this study is to establish a predictive model...
6.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, et al.
Eur Urol
. 2022 Jun;
83(2):163-172.
PMID: 35715365
Background: FH-deficient renal cell carcinoma (RCC) is a rare and exceptionally aggressive RCC subtype. There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy...
7.
Lin D, Lin J, Hu X, Liu Y, Zhang J, Zhang L, et al.
Transl Androl Urol
. 2021 Feb;
10(1):426-437.
PMID: 33532330
Background: Subclinical Cushing's syndrome (SCS) is incidentally detected in a growing number of patients by advanced imaging technology. However, there is no consensus on the clinical management of SCS, especially...
8.
Dai J, He H, Lin D, Wang C, Zhu Y, Xu D
Int J Clin Exp Pathol
. 2020 Jan;
11(12):5792-5800.
PMID: 31949665
Previous studies have reported that double stranded RNAs (dsRNAs) have a potent ability to induce gene expression by targeting its promoter in cancer cells, which is called RNA activation (RNAa)....
9.
Xu F, Lin D, Jiang W, Meng L, Xu Y, Wang C, et al.
Int J Clin Exp Pathol
. 2020 Jan;
12(7):2585-2594.
PMID: 31934086
According to the most recent World Health Organization classification, all pheochromocytomas have metastatic potential. Up until now there has been an absence of effective therapeutic methods to inhibit tumor growth...
10.
Lin D, Lin J, Li X, Zhang J, Lai P, Mao Z, et al.
Front Genet
. 2019 Dec;
10:1181.
PMID: 31803246
Malignant pheochromocytoma (PHEO) can only be fully diagnosed when metastatic foci develop. However, at this point in time, patients gain little benefit from traditional therapeutic methods. Methylation plays an important...